ModerateVitamin K antagonist anticoagulants×Short-to-medium acting systemic glucocorticoid
Updated · Methodology
Mechanism
The acenocoumarol summary of product characteristics (SmPC) lists corticosteroids, including methylprednisolone and prednisone, among drugs that can potentiate the anticoagulant effect of acenocoumarol (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the prednisone SmPC, the anticoagulant effect of coumarin derivatives, which include acenocoumarol, can either decrease or increase (prednisone SmPC, AEMPS). The US prednisone label gives data for warfarin only: the response to warfarin usually weakens, although some reports conflict (prednisone prescribing information, US Food and Drug Administration, FDA). Prednisone itself can cause peptic ulcers and gastrointestinal bleeding (prednisone SmPC, AEMPS), and peptic ulcer and gastrointestinal bleeding are contraindications to acenocoumarol (acenocoumarol SmPC, AEMPS).
Symptoms
The anticoagulant effect of acenocoumarol can either increase or decrease (prednisone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), so the international normalised ratio (INR) can move in either direction. When the INR rises, the main risk is bleeding. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). When the INR falls below the target range, protection against clots, the reason for acenocoumarol treatment, weakens. Prednisone itself can cause peptic ulcers and gastrointestinal bleeding (prednisone SmPC, AEMPS).
Management
The combination is not contraindicated but needs close coagulation monitoring. Among corticosteroids, the acenocoumarol summary of product characteristics (SmPC) places only high intravenous doses of methylprednisolone among combinations that are generally not recommended. Prednisone is on the list of drugs that need close and frequent coagulation checks, for example twice a week, both when they are added and when they are stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When prednisone is given with coumarin derivatives, the anticoagulant dose may need adjusting (prednisone SmPC, AEMPS). For warfarin, the US prednisone label asks for frequent monitoring of coagulation indices to keep the desired anticoagulant effect (prednisone prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose of acenocoumarol is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. Restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Prednisona, Dacortin 2,5 mg (nº registro 47863), sección 4.5 (2026)– AEMPS, CIMA, nº registro 47863 (Dacortin 2,5 mg comprimidos, Laboratorios Ern), revisión 02/2026 (texto revisado 01/2026), secciones 4.2, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Prednisona Cinfa 30 mg (nº registro 75676), sección 4.5 (2026)– AEMPS, CIMA, nº registro 75676 (Prednisona Cinfa 30 mg comprimidos EFG), revisión 02/2026 (texto revisado 01/2026), sección 4.5
- FDA: Prednisone tablets (Mylan) prescribing information (2026)– FDA, DailyMed setid fec09050-5ac2-451b-a2b9-5a21b2def212 (Mylan Pharmaceuticals, Viatris), revisión 09/2026 (versión 10), Precautions: General Precautions y Drug Interactions (Estrogens, Including Oral Contraceptives; Hepatic Enzyme Inducers, Inhibitors and Substrates)
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.3 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.3 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.3
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2